Solid IO
Solid IO builds patient-specific tumor-on-chip systems that produce real-time insights to inform immuno-oncology treatment and drug development. The company combines organ-on-chip bioengineering with microphysiological systems, computational modeling, and artificial intelligence to replicate tumor microenvironments and predict immune responses. Offered as a B2B SaaS platform, Solid IO serves pharmaceutical and biotech companies, cancer clinics, and research centers for patient stratification, preclinical modeling, and clinical-trial optimization. The platform integrates experimental assays with AI-driven analytics and supports partnerships for validation and regulatory use. Solid IO is scaling collaborations to improve translational relevance and accelerate adoption in clinical and R&D settings.
Solid IO
Solid IO builds patient-specific tumor-on-chip systems that produce real-time insights to inform immuno-oncology treatment and drug development. The company combines organ-on-chip bioengineering with microphysiological systems, computational modeling, and artificial intelligence to replicate tumor microenvironments and predict immune responses. Offered as a B2B SaaS platform, Solid IO serves pharmaceutical and biotech companies, cancer clinics, and research centers for patient stratification, preclinical modeling, and clinical-trial optimization. The platform integrates experimental assays with AI-driven analytics and supports partnerships for validation and regulatory use. Solid IO is scaling collaborations to improve translational relevance and accelerate adoption in clinical and R&D settings.